OpRegen

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Age-Related Macular DegenerationGeographic Atrophy

40 competitors in Age-Related Macular Degeneration

#DrugCompanyPhaseTrials

1

Eylea

Regeneron

Approved

372

Zometa

Pfizer

Approved

—3

Bayer Aspirin

Bayer

Approved

—4

Plavix

Sanofi

Approved

—5

Tecfidera

Biogen

Approved

—6

Visudyne

BBausch Health Americas, Inc.

Approved

17

Acetadote

AArbor Pharmaceuticals, Inc.

Approved

—8

Lodosyn

LLaTonya J. Hickson

Approved

—9

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

—10

Bendopa

MMerz North America, Inc.

Approved

—Show 22 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Age-Related Macular Degeneration1 trial

Phase I/IIa Dose Escalation Safety and Efficacy Study of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelium Cells Transplanted Subretinally in Patients With Advanced Dry-Form Age-Related Macular Degeneration (Geographic Atrophy)

Active, not recruiting·Roche·Preclinical·NCT02286089·24 enrolled

Geographic Atrophy1 trial

A Phase IIa, Multicenter, Open-label, Single-Arm Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Recruiting·Roche·Phase 2·NCT05626114·60 enrolled

Details

Drug Info

Related News